Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Hetero-bivalent agents targeting FAP and PSMA

European Journal of Nuclear Medicine and Molecular Imaging(2022)10.1007/s00259-022-05933-3Source: DataRank Database

Hetero-bivalent agents targeting FAP and PSMA is a research paper published in European Journal of Nuclear Medicine and Molecular Imaging (2022). On theSindex it has a DataRank of 0. It has been cited 45 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

45 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 4.00)OA: closedTopics (39)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Alla Lisok,Gabriela Lofland ORCID,Il Minn ORCID,Yu Yan ORCID,Zirui Jiang ORCID

Live enrichment

PubMed:35965291 OpenAlex:https://openalex.org/W4291536065

National Institutes of Health

Grant: CA184228

National Institutes of Health

Grant: EB024495

Deperatment of Defence

Grant: W81XWH2110920

National Institutes of Health

Grant: 2R01CA184228-06

Small Molecule PSMA-Targeted Alpha Therapy

National Institutes of Health

Grant: 5P41EB024495-02

Resource for Molecular Imaging Agents in Precision Medicine

Emerson Collective Cancer Research Fund

FWCI

4.00

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: Springer TDM

publisherhttps://link.springer.com/content/pdf/10.1007/s00259-022-05933-3.pdf

publisherhttps://link.springer.com/article/10.1007/s00259-022-05933-3/fulltext.html

journalhttps://doi.org/10.1007/s00259-022-05933-3

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35965291

Fields of Study

Peptidase Inhibition and AnalysisCancer Research and TreatmentsProstate Cancer Treatment and Research0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Positron Emission Tomography Computed TomographyAnimalsHumansMaleProstatic NeoplasmsTissue DistributionRadiopharmaceuticalsGlutamate Carboxypeptidase IICell Line, TumorPositron-Emission TomographyMiceTumor Microenvironment

Keywords

Bivalent (engine)MedicineCancer researchPharmacologyChemistryPositron emission tomographyProstate-specific membrane antigenFibroblast activation proteinTumor MicroenvironmentCancer-associated FibroblastsMaleGlutamate Carboxypeptidase IIProstatic NeoplasmsMicePositron Emission Tomography Computed TomographyCell Line, TumorPositron-Emission TomographyAnimalsHumansTissue DistributionRadiopharmaceuticals

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being